LY4584180 / Eli Lilly - LARVOL DELTA

NOVA-BCL6-1: A FIRST-IN-HUMAN PHASE 1 TRIAL OF LY4584180, A NOVEL BCL6 MOLECULAR GLUE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (TRIAL IN PROGRESS) (EHA 2026) - P1 | "Table Table Cohort (Treatment) Tumor Type Key Eligibility • B1 (LY4584180) • DLBCL-NOS/HGBCL/FL (grade 3b) • B1a: ≥2 prior lines of therapy including CAR T- cell therapy • B1b: ≥2 prior lines of therapy; no prior CAR T-cell therapy • B2 (LY4584180) • FL (grades 1-3a) • ≥2 prior lines of therapy • B3 (LY4584180) • MZL, MCL, WM/LPL, CLL/SLL • ≥2 prior lines of therapy • CLL/SLL: prior BTK inhibitor + BCL2 inhibitor required • WM/LPL: prior BTK inhibitor required • B4 (LY4584180) • DLBCL transformed from indolent lymphoma • ≥2 prior lines of therapy • B5 (LY4584180 + rituximab) • DLBCL-NOS/HGBCL/FL (grade 3b) • ≥2 prior lines including CAR T-cell therapy unless not a candidate 1 Langan C, et al. Abstract 4594. Poster presented at AACR, April 17-22, 2026"

Clinical • First-in-human • P1 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma • Targeted Protein Degradation • Waldenstrom Macroglobulinemia • BCL6 • CRBN

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers (clinicaltrials.gov) - P1 | N=460 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

LY4584180, a novel BCL6 molecular glue, demonstrates antitumor efficacy in preclinical models of B Cell NHL (AACR 2026) - P1 | "Int J Mol Sci 2024, 25:10968 3Groocock L, et al. Blood 2024; 144 (Supplement 1): 957"

Preclinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL6 • CRBN

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers (clinicaltrials.gov) - P1 | N=360 | Not yet recruiting | Sponsor: Eli Lilly and Company

First-in-human • New P1 trial • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology